<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826811</url>
  </required_header>
  <id_info>
    <org_study_id>6368</org_study_id>
    <nct_id>NCT02826811</nct_id>
  </id_info>
  <brief_title>Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK</brief_title>
  <official_title>Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BKV nephropathy (BKV) is one of the most frequent complications of kidney transplantation.

      In the absence of specific anti-BKV treatment, pre-emptive reduction of immunosuppression is
      the main strategy that has proven effective in reducing the risk of BKVN. However, it exposes
      a transplant rejection risk estimated between 4 and 14% according to studies.

      Despite the pre-emptive reduction of immunosuppression, a significant number of patients
      continue to progress towards BKVN suggesting that pre-emptive strategy is late. It's
      therefore urgent to develop new prognostic markers to identify earlier and more effectively
      patients with a higher risk of developing BKVN.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of anti-BKV</measure>
    <time_frame>up to 12 months post-transplantation</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Graft Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Kidney transplant patients between 1 July 2012 and 31 July 2014 at the University Hospital
        of Strasbourg
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years

          -  Grafted kidney patient between 1 July 2012 and 31 July 2014 at Strasbourg University
             Hospital with regular monitoring

        Exclusion Criteria:

          -  Patient under 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Strasbourg, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
    <phone>33.3.69.55.14.38</phone>
    <email>samira.fafi-kremer@unistra.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Virologie - HÃ´pital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <phone>33.3.69.55.14.38</phone>
      <email>samira.fafi-kremer@unistra.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Graft dysfunction</keyword>
  <keyword>Graft loss</keyword>
  <keyword>kidney</keyword>
  <keyword>Transplantation</keyword>
  <keyword>BKV</keyword>
  <keyword>Anti-BKV</keyword>
  <keyword>Nephropathy</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Prognostic markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

